Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.

Portrait of Prof Anna S.

Commenting on the launch, Professor Anna Schuh, Director of Molecular Diagnostics in the Department of Oncology, said: ‘A precise diagnosis is essential in delivering the right treatment to the right patient and at the right time, however 47% of the global population has little to no access to diagnostics. When it comes to common and potentially curable diseases like some types of anaemia or cancers, a late diagnosis or a misdiagnosis majorly contributes to these diseases’ poor outcomes.’

In sub-Saharan Africa, many diseases that can be easily cured or well controlled with affordable therapies are currently not being diagnosed. For early-stage cancer – adds Schuh - over 90% of patients can be cured in-country with treatment that costs a fraction of those for late-stage cancer.

Read the full story on Oxford Cancer website

Similar stories

New small molecule found to suppress the evolution of antibiotic resistance in bacteria

Researchers from the Ineos Oxford Institute for antimicrobial research (IOI) and the Department of Pharmacology at Oxford University, have developed a new small molecule that can suppress the evolution of antibiotic resistance in bacteria and make resistant bacteria more susceptible to antibiotics.